Literature DB >> 34169737

Effects of Sodium-Glucose Linked Transporter 2 Inhibition With Ertugliflozin on Mitochondrial Function, Energetics, and Metabolic Gene Expression in the Presence and Absence of Diabetes Mellitus in Mice.

Dominique Croteau1, Ivan Luptak1, Jordan M Chambers1, Ion Hobai1, Marcello Panagia1, David R Pimentel1, Deborah A Siwik1, Fuzhong Qin1, Wilson S Colucci1.   

Abstract

Background Inhibitors of the sodium-glucose linked transporter 2 improve cardiovascular outcomes in patients with or without type 2 diabetes mellitus, but the effects on cardiac energetics and mitochondrial function are unknown. We assessed the effects of sodium-glucose linked transporter 2 inhibition on mitochondrial function, high-energy phosphates, and genes encoding mitochondrial proteins in hearts of mice with and without diet-induced diabetic cardiomyopathy. Methods and Results Mice fed a control diet or a high-fat, high-sucrose diet received ertugliflozin mixed with the diet (0.5 mg/g of diet) for 4 months. Isolated mitochondria were assessed for functional capacity. High-energy phosphates were assessed by 31P nuclear magnetic resonance spectroscopy concurrently with contractile performance in isolated beating hearts. The high-fat, high-sucrose diet caused myocardial hypertrophy, diastolic dysfunction, mitochondrial dysfunction, and impaired energetic response, all of which were prevented by ertugliflozin. With both diets, ertugliflozin caused supernormalization of contractile reserve, as measured by rate×pressure product at high work demand. Likewise, the myocardial gene sets most enriched by ertugliflozin were for oxidative phosphorylation and fatty acid metabolism, both of which were enriched independent of diet. Conclusions Ertugliflozin not only prevented high-fat, high-sucrose-induced pathological cardiac remodeling, but improved contractile reserve and induced the expression of oxidative phosphorylation and fatty acid metabolism gene sets independent of diabetic status. These effects of sodium-glucose linked transporter 2 inhibition on cardiac energetics and metabolism may contribute to improved structure and function in cardiac diseases associated with mitochondrial dysfunction, such as heart failure.

Entities:  

Keywords:  cardiac metabolism; diabetic cardiomyopathy; energetics; mitochondria; sodium‐glucose linked transporter 2 inhibitor

Year:  2021        PMID: 34169737     DOI: 10.1161/JAHA.120.019995

Source DB:  PubMed          Journal:  J Am Heart Assoc        ISSN: 2047-9980            Impact factor:   5.501


  18 in total

Review 1.  Comparisons of pleiotropic effects of SGLT2 inhibition and GLP-1 agonism on cardiac glucose intolerance in heart dysfunction.

Authors:  Belma Turan; Aysegul Durak; Yusuf Olgar; Erkan Tuncay
Journal:  Mol Cell Biochem       Date:  2022-05-22       Impact factor: 3.396

Review 2.  Role of Sodium-Glucose Co-Transporter 2 Inhibitors in the Regulation of Inflammatory Processes in Animal Models.

Authors:  Sandra Feijóo-Bandín; Alana Aragón-Herrera; Manuel Otero-Santiago; Laura Anido-Varela; Sandra Moraña-Fernández; Estefanía Tarazón; Esther Roselló-Lletí; Manuel Portolés; Oreste Gualillo; José Ramón González-Juanatey; Francisca Lago
Journal:  Int J Mol Sci       Date:  2022-05-18       Impact factor: 6.208

Review 3.  Targeting the Metabolic-Inflammatory Circuit in Heart Failure With Preserved Ejection Fraction.

Authors:  En Ping Yap; Myu Mai Ja Kp; Chrishan J Ramachandra
Journal:  Curr Heart Fail Rep       Date:  2022-04-11

4.  HMGCS2 silencing attenuates high glucose-induced in vitro diabetic cardiomyopathy by increasing cell viability, and inhibiting apoptosis, inflammation, and oxidative stress.

Authors:  Donglin Chen; Xiang Ruan; Yu Liu; Yan He
Journal:  Bioengineered       Date:  2022-05       Impact factor: 6.832

Review 5.  Sodium-Glucose Cotransporter 2 Inhibitors and Heart Failure: A Bedside-to-Bench Journey.

Authors:  Donato Cappetta; Antonella De Angelis; Gabriella Bellocchio; Marialucia Telesca; Eleonora Cianflone; Daniele Torella; Francesco Rossi; Konrad Urbanek; Liberato Berrino
Journal:  Front Cardiovasc Med       Date:  2021-12-23

6.  Human myocardial mitochondrial oxidative capacity is impaired in mild acute heart transplant rejection.

Authors:  Daniel Scheiber; Elric Zweck; Sophie Albermann; Tomas Jelenik; Maximilian Spieker; Florian Bönner; Patrick Horn; Heinz-Peter Schultheiss; Ganna Aleshcheva; Felicitas Escher; Udo Boeken; Payam Akhyari; Michael Roden; Malte Kelm; Julia Szendroedi; Ralf Westenfeld
Journal:  ESC Heart Fail       Date:  2021-09-06

7.  Attenuation of Adverse Postinfarction Left Ventricular Remodeling with Empagliflozin Enhances Mitochondria-Linked Cellular Energetics and Mitochondrial Biogenesis.

Authors:  Yang Song; Chengqun Huang; Jon Sin; Juliana de F Germano; David J R Taylor; Reetu Thakur; Roberta A Gottlieb; Robert M Mentzer; Allen M Andres
Journal:  Int J Mol Sci       Date:  2021-12-31       Impact factor: 5.923

Review 8.  Podocyte Bioenergetics in the Development of Diabetic Nephropathy: The Role of Mitochondria.

Authors:  Irena Audzeyenka; Agnieszka Bierżyńska; Abigail C Lay
Journal:  Endocrinology       Date:  2022-01-01       Impact factor: 4.736

Review 9.  Neuroprotective Effect of SGLT2 Inhibitors.

Authors:  Agnieszka Pawlos; Marlena Broncel; Ewelina Woźniak; Paulina Gorzelak-Pabiś
Journal:  Molecules       Date:  2021-11-28       Impact factor: 4.411

10.  SGLT2 Inhibition on Cardiac Mitochondrial Function: Searching for a Sweet Spot.

Authors:  Konrad Teodor Sawicki; Issam Ben-Sahra; Elizabeth M McNally
Journal:  J Am Heart Assoc       Date:  2021-06-25       Impact factor: 5.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.